Tonix Pharma Files 8-K with Antibody and PK Data
Ticker: TNXP · Form: 8-K · Filed: Apr 23, 2026 · CIK: 0001430306
Sentiment: neutral
Topics: drug-development, clinical-data, biotech
Related Tickers: TNXP
TL;DR
TNXP dropped an 8-K with new antibody and PK data for TNX-1700. Check the exhibits.
AI Summary
Tonix Pharmaceuticals Holding Corp. filed an 8-K on April 23, 2026, reporting on events from April 21, 2026. The filing includes a press release dated April 22, 2026, and exhibits detailing in vitro characterization of fully human antagonistic anti-BTLA monoclonal antibody and pharmacokinetics of TNX-1700. The company is located at 200 Connell Drive, Suite 3100, Berkeley Heights, NJ 07922.
Why It Matters
This filing provides investors with updated scientific data on Tonix's drug candidates, potentially impacting the perceived value and future development of their pharmaceutical pipeline.
Risk Assessment
Risk Level: medium — The filing contains scientific data that could lead to significant shifts in investor sentiment and valuation, but does not appear to involve immediate financial distress or major corporate changes.
Key Players & Entities
- Tonix Pharmaceuticals Holding Corp. (company) — Filer of the 8-K report
- TNX-1700 (drug_candidate) — Subject of pharmacokinetics study
- anti-BTLA monoclonal antibody (drug_candidate) — Subject of in vitro characterization
- April 23, 2026 (date) — Filing date of the 8-K
- April 21, 2026 (date) — Period of report for the 8-K
- April 22, 2026 (date) — Date of the press release included in the filing
FAQ
What is the primary purpose of the 8-K filing by Tonix Pharmaceuticals Holding Corp. on April 23, 2026?
The 8-K filing on April 23, 2026, serves as a current report for Tonix Pharmaceuticals Holding Corp., detailing events from April 21, 2026, and including a press release and scientific exhibits.
What specific scientific data is presented in the exhibits of this 8-K filing?
The exhibits include details on the in vitro characterization of a fully human antagonistic anti-BTLA monoclonal antibody and the pharmacokinetics of TNX-1700 in non-human primates and human FCRN/serum albumin.
What is the filing date and the period of report for this 8-K?
The 8-K was filed on April 23, 2026, and the period of report is April 21, 2026.
Where is Tonix Pharmaceuticals Holding Corp. located?
Tonix Pharmaceuticals Holding Corp. is located at 200 Connell Drive, Suite 3100, Berkeley Heights, NJ 07922.
What are the key document types included in this 8-K filing?
The filing includes a current report (iXBRL 8-K), a press release, and several exhibits (EX-99.01, EX-99.02, EX-99.03) containing scientific data and graphics, along with XBRL data files.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 23, 2026 regarding Tonix Pharmaceuticals Holding Corp. (TNXP).